Indapta Therapeutics

Venture capital mega-rounds of $100m or more have surged in 2024 and the trend has continued in December, with announcements on 19 December that Ottimo Pharma’s series A round brought in more than $14

Bayer AG 's corporate venture arm has invested more than €1.3bn since 2015 and intends to match that sum from now through 2024 to support biotechs developing innovative technologies in healthcare. At

Twelve biopharmaceutical companies announced venture capital financings totaling $672m between 7 and 11 February, which was another relatively quiet week for public company offerings. With biotechnolo